key: cord-1036103-42tzg7jy
authors: Dufour, Inès; Raedemaeker, Juliette; Andreozzi, Fabio; Verstraete, Géraldine; Bailly, Sarah; Delforge, Michel; Storms, Pauline; Jacquy, Caroline; Van de Velde, Ann; Mineur, Philippe; Lejeune, Marie; Bauwens, Deborah; Van Obbergh, Florence; Kentos, Alain; Nguyen, Jasmine; Fostier, Karel; De Weweire, Anne; Meuleman, Nathalie; Vekemans, Marie-Christiane
title: COVID-19, impact on myeloma patients
date: 2020-06-23
journal: Ann Hematol
DOI: 10.1007/s00277-020-04147-7
sha: fdcac7273cea840aa68f51dcc591e1d0f274a747
doc_id: 1036103
cord_uid: 42tzg7jy

nan

. Our data support also the need to reduce at least the dexamethasone dosage, as proposed by others [4, 5] . Grade 4 eosinopenia is common [6] , a possible landmark feature of COVID-19. Further investigations are mandatory in order to assess the impact of this new viral infection on MM patients.

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Interim clinical guidance for adults with suspected or confirmed covid-19 in Belgium

Is ethnicity linked to incidence or outcomes of Covid-19?

Management of patients with multiple myeloma during the COVID-19 pandemic

COVID-19 and multiple myeloma: frequently asked questions, version 1.1, last updated

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations